Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].
作者信息
Ou Sai-Hong Ignatius, Cui Jean, Schrock Alexa B, Goldberg Michael E, Zhu Viola W, Albacker Lee, Stephens Philip J, Miller Vincent A, Ali Siraj M
机构信息
Chao Family Comprehensive Cancer Center, University of California, Irvine School of Medicine, Orange, CA, USA.
TP Therapeutics Inc, San Diego, CA, USA.
出版信息
Lung Cancer. 2019 Dec;138:141. doi: 10.1016/j.lungcan.2019.08.013. Epub 2019 Aug 22.
Abstract
摘要
Zotero 插件